KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non Operating Income: 2019-2024

Historic Non Operating Income for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $14.2 million.

  • Recursion Pharmaceuticals' Non Operating Income rose 271.48% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year decrease of 29.82%. This contributed to the annual value of $14.2 million for FY2024, which is 20.72% down from last year.
  • Recursion Pharmaceuticals' Non Operating Income amounted to $14.2 million in FY2024, which was down 20.72% from $17.9 million recorded in FY2023.
  • Recursion Pharmaceuticals' Non Operating Income's 5-year high stood at $17.9 million during FY2023, with a 5-year trough of -$3.7 million in FY2021.
  • In the last 3 years, Recursion Pharmaceuticals' Non Operating Income had a median value of $14.2 million in 2024 and averaged $12.8 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Non Operating Income plummeted by 525.44% in 2020, and later spiked by 268.76% in 2022.
  • Recursion Pharmaceuticals' Non Operating Income (Yearly) stood at -$2.4 million in 2020, then tumbled by 54.91% to -$3.7 million in 2021, then soared by 268.76% to $6.3 million in 2022, then spiked by 186.87% to $17.9 million in 2023, then declined by 20.72% to $14.2 million in 2024.